18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

24 August 2020 - Event

4th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered Digitally

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…

09 July 2020 - Event

Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

The world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflexion paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

BEAM News
Member News
Events

Latest news of BEAM Alliance

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflexion paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

23 June 2020 - BioVersys AG

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of a fixed combination of BVL-GSK098 and ETH

Dr. Sergio Lociuro, Chief Scientific Officer of BioVersys: “The combination of BVL-GSK098 and ETH offers a novel, fast acting anti-tuberculosis…

29 May 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

18 May 2020 - Nabriva Therapeutics GmbH

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

14 May 2020 - Polyphor Ltd

Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program

Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer…

06 May 2020 - ANTABIO S.A.S

Antabio Receives QIDP Designation from the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Martin Everett, Chief Scientific Officer of Antabio said: “The receipt of the QIDP designation is an important regulatory milestone for…

05 May 2020 - Nabriva Therapeutics GmbH

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

XENLETA™ is a first-in-class pleuromutilin antibiotic approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired…

page 1/19

Events

26 October 2020

BIO-Europe® 2020 Digital – 26th Annual International Partnering Conference

The 26th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe, though in 2020 by necessity we…

21 September 2020

BioPharm America™ 2020 Digital —13th Annual International Partnering Conference

For this year’s digital event, BioPharm America will focus on Innovation and Investing, with the added collaboration of a number…

25 August 2020

ChinaBio ® Partnering Forum 2020 Digital

ChinaBio® Partnering Forum is the largest and most productive China-focused life science partnering event. To be held as a digital…

24 August 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered Digitally

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…

13 July 2020

Curious2020 – Future Insight Virtual Event

This event will feature three key global initiatives to support further advancement in science & technology, solving the challenges of…

09 July 2020

REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

In this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…

09 July 2020

Webinar: Antimicrobial Resistance (AMR): Phenotypic vs. Target-Based Screening

The webinar intends to motivate a revision of the way we feed the research funnel with new ideas, new biology…

09 July 2020

Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

The world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…

30 June 2020

REVIVE Webinar: Clinical development of antimicrobials – Phase 1 development challenges

Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)

page 1/7